Study of Blood Clot Breakdown Resistance in Patients with Severe Infection or Trauma in Intensive Care

What this Trial Is About

Blood clotting problems often occur in critically ill patients, such as those with severe infections or serious injuries, which can lead to life-threatening complications like organ failure due to excessive clot formation. This research is focused on using Viscoelastic Testing VET technology to identify patients at risk of excessive clotting, evaluate new blood clotting drugs, and guide the use of blood-altering treatments in critical care settings. The study aims to better understand why fibrinolysis resistance happens in severe infections and trauma, which may improve personalized treatment approaches. The study uses Viscoelastic Testing technology called ClotPro4 to assess blood clot breakdown activity by analyzing key proteins involved in fibrinolysis. It observes patients with sepsis or trauma admitted to intensive care units ICUs who meet specific clinical criteria, including those expected to stay in ICU beyond the immediate days and requiring organ support or blood transfusion risk. The project involves testing blood samples at multiple time points after ICU admission to study clotting activity and response to potential treatments. Participants will undergo blood testing using VET at admission and at 24 hours, 48 hours, 5, 7, 10, and 15 days after ICU admission. Researchers will analyze blood clotting and fibrinolysis profiles to detect abnormalities and understand enzyme activity changes. The study will monitor patients closely in ICU with laboratory evaluations and data collection to inform future clinical trials aimed at personalizing treatment for fibrinolysis resistance. Total participation time varies depending on ICU stay and recovery.

Fibrinolysis Resistance in Infection and Trauma